Kronos Bio 관리

관리 기준 확인 2/4

Kronos Bio CEO는 Norbert Bischofberger, Aug2018 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 $ 1.76M, 32.9% 로 구성됩니다. 32.9% 급여 및 67.1% 보너스(회사 주식 및 옵션 포함). 는 $ 11.10M 가치에 해당하는 회사 주식의 21.03% 직접 소유합니다. 11.10M. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 5.4 년입니다.

주요 정보

Norbert Bischofberger

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	32.9%
CEO 임기	6.3yrs
CEO 소유권	21.0%
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09

Kronos Bio  EPS misses by $4.10

Nov 18

CEO 보상 분석

Norbert Bischofberger 의 보수는 Kronos Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$86m
Jun 30 2024	n/a	n/a	-US$103m
Mar 31 2024	n/a	n/a	-US$116m
Dec 31 2023	US$2m	US$580k	-US$113m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$120m
Mar 31 2023	n/a	n/a	-US$123m
Dec 31 2022	US$3m	US$580k	-US$133m
Sep 30 2022	n/a	n/a	-US$164m
Jun 30 2022	n/a	n/a	-US$165m
Mar 31 2022	n/a	n/a	-US$161m
Dec 31 2021	US$645k	US$320k	-US$151m
Sep 30 2021	n/a	n/a	-US$122m
Jun 30 2021	n/a	n/a	-US$128m
Mar 31 2021	n/a	n/a	-US$108m
Dec 31 2020	US$15m	US$399k	-US$88m
Sep 30 2020	n/a	n/a	-US$61m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$280k	US$200k	-US$16m

보상 대 시장: Norbert 의 총 보상 ($USD 1.76M )은 US 시장( $USD 650.80K ).

보상과 수익: Norbert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Norbert Bischofberger (68 yo)

6.3yrs

테뉴어

US$1,761,537

보상

Dr. Norbert W. Bischofberger, Ph D., is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He has been an Independent Director of Morphic Holding, Inc. since June 14, 2019.Dr. Bischofberge...

리더십 팀

이름	위치	테뉴어	보상	소유권
Norbert Bischofberger	President	6.3yrs	US$1.76m	21.03% $ 11.1m
Joshua Kazam	Co-Founder & Director	no data	US$74.80k	0.61% $ 320.7k
David Tanen	Secretary & Director	no data	US$74.80k	1.52% $ 799.5k
Deborah Knobelman	COO & CFO	less than a year	데이터 없음	0.27% $ 143.7k
Charles Lin	Chief Scientific Officer	less than a year	데이터 없음	0.39% $ 205.3k
Allison Frisbee	Chief Administrative Officer	less than a year	데이터 없음	0.34% $ 178.9k
Margaux Bennett	Vice President of Corporate Development & Investor Relations	3.5yrs	데이터 없음	데이터 없음
Elizabeth Olek	Senior Vice President of Clinical Development	2.8yrs	데이터 없음	0.32% $ 169.1k
Wes Trotter	Senior Vice President of Drug Discovery & Pharmaceutical Development	1.6yrs	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: KRON 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Norbert Bischofberger	President	6.6yrs	US$1.76m	21.03% $ 11.1m
Joshua Kazam	Co-Founder & Director	7.4yrs	US$74.80k	0.61% $ 320.7k
David Tanen	Secretary & Director	7.4yrs	US$74.80k	1.52% $ 799.5k
Owen Witte	Scientific Advisory Board Chairman	no data	데이터 없음	데이터 없음
Arie Belldegrun	Independent Chairman of the Board	7yrs	US$117.20k	1.13% $ 594.6k
Elena Ridloff	Independent Director	4.2yrs	US$89.17k	0.042% $ 22.1k
Taiyin Yang	Independent Director	3.7yrs	US$88.70k	0.019% $ 9.9k
Roshawn Blunt	Independent Director	3yrs	US$79.80k	0% $ 0
Angela Koehler	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Robert Eisenman	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Myles Brown	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Katherine Stultz	Independent Director	1.7yrs	US$105.68k	0% $ 0

5.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: KRON 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Kronos Bio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

President recently bought US$734k worth of stock

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

President recently bought US$3.1m worth of stock

Kronos Bio, Inc. Appoints Deborah Knobelman as Chief Financial Officer, Effective June 3, 2024

Kronos Bio, Inc., Annual General Meeting, Jun 25, 2024

Kronos Bio, Inc. Announces Executive Changes

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 62% to US$1.63

Kronos Bio Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio, Inc. Announces Selection of Autoimmune Development Candidate for Sjogren's Disease

Consensus EPS estimates upgraded to US$1.35 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kronos Bio, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2024

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

President recently bought US$734k worth of stock

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

President recently bought US$3.1m worth of stock

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Kronos Bio, Inc. Appoints Deborah Knobelman as Chief Financial Officer, Effective June 3, 2024

Kronos Bio: Underestimated Drug Discovery Platform

Kronos Bio, Inc., Annual General Meeting, Jun 25, 2024

Kronos Bio Plans to Reduction in Force

New minor risk - Insider selling

Kronos Bio, Inc. Announces Executive Changes

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

President recently bought US$1.5m worth of stock

New minor risk - Share price stability

Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting

Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC

Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer

Price target decreased by 14% to US$9.00

Consensus revenue estimates decrease by 17%

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Kronos Bio Announces Resignation of Yasir Al-Wakeel as Chief Financial Officer, Effective from September 15, 2023

Consensus revenue estimates increase by 17%, EPS downgraded

New minor risk - Shareholder dilution

Price target increased by 7.5% to US$10.75

Kronos Bio, Inc. Appoints Marc Besman as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Consensus revenue estimates decrease by 17%

Consensus EPS estimates upgraded to US$1.84 loss

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Marianne De Backer to Resign from Board of Directors of Kronos Bio, Inc

Kronos Bio, Inc. Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Kronos Bio, Inc. Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Price target decreased to US$16.60

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Kronos Bio, Inc.(NasdaqGS:KRON) dropped from Russell 2000 Growth Index

Price target decreased to US$25.25

President recently bought US$2.3m worth of stock

Price target decreased to US$31.25

Price target decreased to US$36.25

Kronos Bio, Inc. Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Insider recently sold US$203k worth of stock

President recently bought US$173k worth of stock

Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

Kronos Bio, Inc Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

Chief Scientific Officer exercised options and sold US$161k worth of stock

Chief Scientific Officer exercised options and sold US$171k worth of stock

Chief Scientific Officer exercised options and sold US$159k worth of stock

Independent Director Jakob Loven has left the company

Kronos Bio, Inc. Announces Receipt of Minutes from the End-Of-Phase 2 Meeting with the U.S. Food and Drug Administration

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Kronos Bio, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Kronos Bio, Inc. Enters into an Amendment to Its Office Lease Dated July 19, 2018 with MPVCA San Mateo LLC

Independent Director has left the company

Kronos Bio EPS misses by $4.10